Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B

Abstract

The genotype G/T for rs8099917 of IL-28 gene and early fibrosis stage may be predictive of treatment success.

Prediction Model for the Clearance of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B before Interferon Therapy: A Prospective Case–Control Study

“…PAK4 regulates cytoskeleton remodeling and affects directional movement, invasion, metastasis, and growth [ 28 ]. The rs9676717 SNP in PAK4 was independently associated with the response to IFN in Chinese patients with CHB [ 29 ]. The IL-28B gene encodes IFN-λ3 and plays an antiviral role by activating the JAK-STAT signal pathway [ 30 ].…”

Controversial Issues in Current Treatment of Chronic HBV Infection

“…So far, a variety of factors has been studied with different results depending on the patients' HBeAg status. In HBeAg-positive CHB patients, the duration of consolidation therapy after HBeAg seroconversion [25][26][27][28], age [29,30], serum HBV DNA and ALT levels at baseline [25,28], HBV genotype [31], and interleukin 28 B (IL-28B) genotype (IFNλ3/4) [32] have all been suggested as possible factors affecting the probability of sustained response after NA discontinuation. In HBeAg-negative CHB patients, younger age [33,34], earlier disease stage [35,36], higher levels of ALT at baseline and at the end of treatment [31,37], lower serum HBV DNA levels at baseline [37, 38•], low serum HBsAg levels at the end of treatment [37,39], or decreasing HBsAg levels during therapy [39][40][41] have all been associated with a better chance of sustained offtreatment response.…”

Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B

“…showed an effect of the IL-28B (IFNλ3/4) genotype on the response to LAM at one year (Yu et al, 2013). Among 33 single-nucleotide polymorphisms (SNPs) from 16 immune-related genes, a recent study found that genetic variations in the CXCR5 gene decrease the risk of clinical relapse after NA discontinuation in CHB patients and thus these genotypes could facilitate optimization of NA discontinuation (Wu et al, 2020, p. 5).…”